The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have extensive stage small cell lung cancer. The purpose of this study is to see if the study drug, called alisertib, can help people with extensive stage small cell lung cancer. The study will also look at how well people tolerate treatment with alisertib.
As part of this study, you will take 50 mg alisertib by mouth, twice daily on Days 1 to 7 of every 21-day cycle.
If you choose to be in this study, the exact length of time you are on the study will depend on how you are doing. You can remain in the study receiving alisertib as long as you are not having serious side effects, your cancer is not getting worse or you withdraw consent.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT06095505
No Compensation